Arcturus Therapeutics
ARCT
22 hedge funds and large institutions have $9.58M invested in Arcturus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
37% more capital invested
Capital invested by funds: $6.98M → $9.58M (+$2.59M)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
22% more funds holding
Funds holding: 18 → 22 (+4)
2.44% more ownership
Funds ownership: 7.65% → 10.09% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$274K |
| 3 |
JP Morgan Chase
New York
|
+$66.7K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$45.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$152K |
| 2 |
Morgan Stanley
New York
|
-$40.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$40.3K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$16K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$9K |
ARCT Hedge Fund Activity: Q3 2018 in Review
22 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2018, worth a combined $9.58M — up 37% from $6.98M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ARCT positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $2M. The largest seller was Oxford Asset Management, cutting an estimated $152K.
- 22 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2018, up from 18 in Q2 2018.
- Funds reported $9.58M of Arcturus Therapeutics stock for Q3 2018, up 37% quarter-over-quarter.
- 7 funds opened new Arcturus Therapeutics positions in Q3 2018 and 3 closed out, a net change of +4 holders.
- The largest Arcturus Therapeutics buyer in Q3 2018 was ARK Investment Management, an estimated $2M added.
- The largest Arcturus Therapeutics seller in Q3 2018 was Oxford Asset Management, an estimated $152K sold.
Based on aggregated 13F filings for Q3 2018.